{
    "clinical_study": {
        "@rank": "132878", 
        "arm_group": [
            {
                "arm_group_label": "normal hepatic function", 
                "arm_group_type": "Experimental", 
                "description": "12 Patients will receive a 90-minute IV infusion"
            }, 
            {
                "arm_group_label": "mild hepatic dysfunction", 
                "arm_group_type": "Experimental", 
                "description": "6 Patients will receive a 90-minute IV infusion"
            }, 
            {
                "arm_group_label": "moderate hepatic dysfunction", 
                "arm_group_type": "Experimental", 
                "description": "6 Patients will receive a 90-minute IV infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with\n      mild or moderate hepatic impairment."
        }, 
        "brief_title": "A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "Safety and PK data from patients with mild or moderate hepatic impairment will be compared\n      with a control group consisting of patients with normal hepatic function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Relapsed or progressive advanced solid tumor malignancies\n\n          -  Measurable or non-measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\n          -  Life expectancy greater than 3 months\n\n          -  Resolution of all acute toxic effects of prior chemotherapy,  and other cancer\n             treatments\n\n          -  Adequate bone morrow and kidney function\n\n          -  No signs of decompensated liver cirrhosis or ascites requiring therapeutic\n             paracentesis\n\n          -  Agree to use adequate contraception\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy, immunotherapy, chemo-embolization, targeted therapy or\n             investigational agent for malignancy within 4 weeks prior to day 1\n\n          -  Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1\n\n          -  Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing\n             grapefruit or Seville oranges within 14 days prior to day 1\n\n          -  UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one\n             or both alleles (hetero- or homozygous for UGT1A1*37)\n\n          -  Major surgery within 4 weeks prior to day 1\n\n          -  Undergone a liver or other organ transplant\n\n          -  Concurrent treatment with other anti-cancer therapy\n\n          -  Untreated central nervous system metastases\n\n          -  Ongoing or active infection\n\n          -  Chronic or acute GI disorders resulting in diarrhea\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991678", 
            "org_study_id": "12-102-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "normal hepatic function", 
                "intervention_name": "145 mg/m2 NKTR 102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "mild hepatic dysfunction", 
                "intervention_name": "120 mg/m2 NKTR 102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "moderate hepatic dysfunction", 
                "intervention_name": "95 mg/m2 NKTR 102", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Zeno.Ashai@med.usc.edu", 
                    "last_name": "Zeno Ashai", 
                    "phone": "323-865-0463"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90089"
                    }, 
                    "name": "USC/Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Anthony El-Khoueiry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fiermontep@cc.ucsf.edu", 
                    "last_name": "Paula Fiermonte, MD", 
                    "phone": "415-885-7605"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF Helen Diller Family Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Pamela Munster, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcca0313@umn.edu", 
                    "last_name": "Carrie McCann", 
                    "phone": "612-626-2569"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Edward Greeno, Jr., MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Robin.Norris@UHhospitals.org", 
                    "last_name": "Robin Norris, MD", 
                    "phone": "216-844-3345"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Seidman Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Robin Norris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment", 
        "overall_contact": {
            "last_name": "Charleen Jue", 
            "phone": "415-482-5300"
        }, 
        "overall_official": {
            "affiliation": "Nektar Therapeutics", 
            "last_name": "Charleen Jue", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1 pre-dose PK measurements 14 post-dose PK measurements", 
            "measure": "Pharmacokinetics (PK) of NKTR-102 and its metabolites", 
            "safety_issue": "No", 
            "time_frame": "Day 1 through Day 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991678"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessments are: physical examinations, vital signs, ECGs, AEs, and laboratory testing.", 
            "measure": "Safety and tolerability of NKTR-102", 
            "safety_issue": "Yes", 
            "time_frame": "Day 1 through Day 42"
        }, 
        "source": "Nektar Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nektar Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}